Follow
Ari Brekkan
Ari Brekkan
Pharmetheus
Verified email at pharmetheus.com
Title
Cited by
Cited by
Year
Population pharmacokinetics of plasma‐derived factor IX: procedures for dose individualization
A Brekkan, E Berntorp, K Jensen, EI Nielsen, S Jönsson
Journal of Thrombosis and Haemostasis 14 (4), 724-732, 2016
412016
A population pharmacokinetic-pharmacodynamic model of pegfilgrastim
A Brekkan, L Lopez-Lazaro, G Yngman, EL Plan, C Acharya, AC Hooker, ...
The AAPS journal 20 (5), 91, 2018
232018
Model‐based evaluation of low‐dose factor VIII prophylaxis in haemophilia A
A Brekkan, J Degerman, S Jönsson
Haemophilia 25 (3), 408-415, 2019
102019
Handling underlying discrete variables with bivariate mixed hidden Markov models in NONMEM
A Brekkan, S Jönsson, MO Karlsson, EL Plan
Journal of Pharmacokinetics and Pharmacodynamics 46, 591-604, 2019
72019
Sensitivity of pegfilgrastim pharmacokinetic and pharmacodynamic parameters to product differences in similarity studies
A Brekkan, L Lopez-Lazaro, EL Plan, J Nyberg, S Kankanwadi, ...
The AAPS Journal 21 (5), 85, 2019
22019
Reduced and optimized trial designs for drugs described by a target mediated drug disposition model
A Brekkan, S Jönsson, MO Karlsson, AC Hooker
Journal of Pharmacokinetics and Pharmacodynamics 45, 637-647, 2018
22018
Characterization of anti-drug antibody dynamics using a bivariate mixed hidden-markov model by nonlinear-mixed effects approach
A Brekkan, R Lledo-Garcia, B Lacroix, S Jönsson, MO Karlsson, EL Plan
Journal of Pharmacokinetics and Pharmacodynamics, 1-11, 2023
2023
Population pharmacokinetics and pharmacodynamics of efmarodocokin alfa (IL-22Fc)
Y Yu, ME Rothenberg, HT Ding, A Brekkan, G Sperinde, B Harder, ...
Journal of Pharmacokinetics and Pharmacodynamics, 1-13, 2023
2023
Bimekizumab in moderate-to-severe plaque psoriasis: population pharmacokinetic and pharmacodynamic relationships
P Vajjah, C Acharya, A Brekkan, M Zamacona, M Nemansky, L Peterson, ...
BRITISH JOURNAL OF DERMATOLOGY 186 (1), E47-E48, 2022
2022
Investigating the identifiability of one-stage IVIVC population models for extended-release dosage forms
S Zannoni, A Brekkan, G Smania
Model based support to biosimilarity assessment planning–A case study of pegfilgrastim
A Brekkan, L Lopez-Lazaro, EL Plan, C Acharya, G Yngman, J Nyberg, ...
The system can't perform the operation now. Try again later.
Articles 1–11